Home » Topics » BioWorld Science

BioWorld Science
RSS

Gene therapy based on newly discovered EBP50 mutation improves neuropathy

Nov. 9, 2018

Tempest Therapeutics discloses prostanoid EP4 receptor antagonists

Nov. 9, 2018

Neurotensin type 1 receptor pepducin PP-001 shows analgesic activity in vivo

Nov. 9, 2018

Activated mesenchymal stem cells show robust preclinical results for treating ischemic stroke

Nov. 9, 2018

Takeda Pharmaceutical presents first preclinical results for LSD1 inhibitor T-448

Nov. 9, 2018

Neurotensin (8-13) analogue demonstrates anxiolytic potential in chronic pain models

Nov. 9, 2018

In situ delivery and retention of cytotoxic drugs with AvidinOX improve their antitumor efficacy

Nov. 9, 2018

Neurocrine Biosciences presents SLC18A2 inhibitors

Nov. 9, 2018

Aquinnah Pharmaceuticals divulges new TDP-43 aggregation inhibitors

Nov. 9, 2018

Cell-combination delivery of anti-PD-1 antibody induces potent antileukemia responses in mice

Nov. 9, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...